Published in Gastroenterol Hepatol on October 01, 2013
Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report. Gut (2012) 12.62
Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet (2012) 5.12
Optimum duration of regimens for Helicobacter pylori eradication. Cochrane Database Syst Rev (2013) 2.53
Accuracy of GastroPanel for the diagnosis of atrophic gastritis. Eur J Gastroenterol Hepatol (2014) 2.49
Optimized nonbismuth quadruple therapies cure most patients with Helicobacter pylori infection in populations with high rates of antibiotic resistance. Gastroenterology (2013) 2.49
Joint position statement by “Sociedad Española de Patología Digestiva” (Spanish Society of Gastroenterology) and “Sociedad Española de Farmacología” (Spanish Society of Pharmacology) on biosimilar therapy for inflammatory bowel disease. Rev Esp Enferm Dig (2013) 2.09
[Current management of nonvariceal upper gastrointestinal bleeding in Spain]. Gastroenterol Hepatol (2012) 2.04
Should we monitor vitamin B12 and folate levels in Crohn's disease patients? Scand J Gastroenterol (2013) 2.04
Probable diffuse retinopathy caused by adalimumab in a patient with Crohn's disease. J Crohns Colitis (2012) 1.98
Randomised clinical trial comparing sequential and concomitant therapies for Helicobacter pylori eradication in routine clinical practice. Gut (2013) 1.79
Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: special situations. J Crohns Colitis (2012) 1.71
Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants. Am J Gastroenterol (2007) 1.67
Addition of a second endoscopic treatment following epinephrine injection improves outcome in high-risk bleeding ulcers. Gastroenterology (2004) 1.55
Efficacy of different therapeutic options for spontaneous abdominal abscesses in Crohn's disease: are antibiotics enough? Inflamm Bowel Dis (2011) 1.50
Common misconceptions in the diagnosis and management of anemia in inflammatory bowel disease. Am J Gastroenterol (2008) 1.49
Thiopurine-induced myelotoxicity in patients with inflammatory bowel disease: a review. Am J Gastroenterol (2008) 1.49
Soluble angiogenic factors in patients with acute pancreatitis. J Clin Gastroenterol (2011) 1.47
Outcomes of pregnancies fathered by inflammatory bowel disease patients exposed to thiopurines. Am J Gastroenterol (2010) 1.47
[Eradication treatment of Helicobacter pylori. Recommendations of the II Spanish Consensus Conference]. Med Clin (Barc) (2005) 1.47
Effectiveness of adalimumab in perianal fistulas in crohn's disease patients naive to anti-TNF therapy. J Clin Gastroenterol (2015) 1.45
Evaluation of liver fibrosis by transient elastography in methotrexate treated patients. Med Clin (Barc) (2011) 1.42
[Common errors in the management of outpatients with inflammatory bowel disease]. Gastroenterol Hepatol (2007) 1.41
Identification of MYH mutation carriers in colorectal cancer: a multicenter, case-control, population-based study. Clin Gastroenterol Hepatol (2007) 1.38
[Thiopurine methyltransferase activity in inflammatory bowel disease. A study on 7046 Spanish patients]. Med Clin (Barc) (2005) 1.38
[Must immunomodulators be added to biological treatment in inflammatory bowel disease?]. Gastroenterol Hepatol (2009) 1.38
Clinical patterns and outcomes of ischaemic colitis: results of the Working Group for the Study of Ischaemic Colitis in Spain (CIE study). Scand J Gastroenterol (2010) 1.33
Anemia and inflammatory bowel diseases. World J Gastroenterol (2009) 1.32
Safety of thiopurine therapy in inflammatory bowel disease: long-term follow-up study of 3931 patients. Inflamm Bowel Dis (2013) 1.31
The stool antigen test for detection of Helicobacter pylori after eradication therapy. Ann Intern Med (2002) 1.25
Prevalence and factors related to hepatitis B and C in inflammatory bowel disease patients in Spain: a nationwide, multicenter study. Am J Gastroenterol (2009) 1.23
Does fecal calprotectin predict relapse in patients with Crohn's disease and ulcerative colitis? J Crohns Colitis (2009) 1.18
A guide to diagnosis of iron deficiency and iron deficiency anemia in digestive diseases. World J Gastroenterol (2009) 1.09
Doubling the infliximab dose versus halving the infusion intervals in Crohn's disease patients with loss of response. Inflamm Bowel Dis (2012) 1.08
Reviewing the mechanism of action of thiopurine drugs: towards a new paradigm in clinical practice. Med Sci Monit (2004) 1.07
Quadruple therapy for Helicobacter pylori infection. Lancet (2013) 1.06
The prevalence of peptic ulcer not related to Helicobacter pylori or non-steroidal anti-inflammatory drug use is negligible in southern Europe. Helicobacter (2004) 1.05
Treatment of Helicobacter pylori infection 2012. Helicobacter (2012) 1.02
Treatment of Helicobacter pylori infection 2010. Helicobacter (2010) 1.00
Nonbismuth quadruple (concomitant) therapy: empirical and tailored efficacy versus standard triple therapy for clarithromycin-susceptible Helicobacter pylori and versus sequential therapy for clarithromycin-resistant strains. Helicobacter (2012) 0.98
Role of 5-aminosalicylic acid (5-ASA) in treatment of inflammatory bowel disease: a systematic review. Dig Dis Sci (2002) 0.98
Timing of surgery in Crohn's disease: a key issue in the management. World J Gastroenterol (2008) 0.98
Treatment of Helicobacter pylori infection 2011. Helicobacter (2011) 0.97
High smoking cessation rate in Crohn's disease patients after physician advice--the TABACROHN Study. J Crohns Colitis (2012) 0.97
Crohn's disease: a review of current treatment with a focus on biologics. Drugs (2007) 0.96
Has H. pylori prevalence in bleeding peptic ulcer been underestimated? A meta-regression. Am J Gastroenterol (2011) 0.96
Treatment of Helicobacter pylori infection 2013. Helicobacter (2013) 0.96
Improving pharmacovigilance in Europe: TPMT genotyping and phenotyping in the UK and Spain. Eur J Hum Genet (2009) 0.95
Induction of CD36 and thrombospondin-1 in macrophages by hypoxia-inducible factor 1 and its relevance in the inflammatory process. PLoS One (2012) 0.95
Current management of iron deficiency anemia in inflammatory bowel diseases: a practical guide. Drugs (2013) 0.95
Ten-day sequential treatment for Helicobacter pylori eradication in clinical practice. Am J Gastroenterol (2008) 0.94
Key points for designing and reporting Helicobacter pylori therapeutic trials: a personal view. Helicobacter (2011) 0.93
Utility of subtyping intestinal metaplasia as marker of gastric cancer risk. A review of the evidence. Int J Cancer (2013) 0.91
Epinephrine injection versus epinephrine injection and a second endoscopic method in high-risk bleeding ulcers. Cochrane Database Syst Rev (2014) 0.91
Epidemiological risk factors in microscopic colitis: a prospective case-control study. Inflamm Bowel Dis (2013) 0.91
Accuracy of computed tomographic colonography for the detection of polyps and colorectal tumors: a systematic review and meta-analysis. Digestion (2009) 0.90
A genome-wide association study on a southern European population identifies a new Crohn's disease susceptibility locus at RBX1-EP300. Gut (2012) 0.90
Induction of psoriasis with anti-TNF agents in patients with inflammatory bowel disease: a report of 21 cases. J Crohns Colitis (2011) 0.90
Observational study on the efficacy of adalimumab for the treatment of ulcerative colitis and predictors of outcome. J Crohns Colitis (2012) 0.90
Tuberculous chemoprophylaxis requirements and safety in inflammatory bowel disease patients prior to anti-TNF therapy. Inflamm Bowel Dis (2008) 0.89
[III Spanish Consensus Conference on Helicobacter pylori infection]. Gastroenterol Hepatol (2013) 0.88
P-selectin glycoprotein ligand-1 modulates immune inflammatory responses in the enteric lamina propria. J Pathol (2011) 0.88
Chronic hepatitis C and Crohn's disease: nosocomial infection treatment with PEG-interferon plus ribavirin. Digestion (2006) 0.87
Adverse events of thiopurine immunomodulators in patients with inflammatory bowel disease. Gastroenterol Hepatol (2011) 0.87
Does smoking influence Crohn's disease in the biologic era? The TABACROHN study. Inflamm Bowel Dis (2013) 0.87
Infliximab rescue therapy after cyclosporin failure in steroid-refractory ulcerative colitis. Digestion (2009) 0.86
Thiopurine methyltransferase activity in Spain: a study of 14,545 patients. Dig Dis Sci (2007) 0.86
Delphi consensus statement: Quality Indicators for Inflammatory Bowel Disease Comprehensive Care Units. J Crohns Colitis (2013) 0.85
Role of vascular endothelial growth factor and angiopoietin systems in serum of Crohn's disease patients. Inflamm Bowel Dis (2008) 0.85
What is potent acid inhibition, and how can it be achieved? Drugs (2005) 0.85
Esophageal motor abnormalities in eosinophilic esophagitis identified by high-resolution manometry. J Gastroenterol Hepatol (2011) 0.84
A review of rescue regimens after clarithromycin-containing triple therapy failure (for Helicobacter pylori eradication). Expert Opin Pharmacother (2013) 0.84
Treatment of Helicobacter pylori infection 2014. Helicobacter (2014) 0.84
Infliximab maintenance therapy is associated with decreases in direct resource use in patients with luminal or fistulizing Crohn's disease. J Clin Gastroenterol (2009) 0.83
Common misconceptions about 5-aminosalicylates and thiopurines in inflammatory bowel disease. World J Gastroenterol (2011) 0.83
Influence of thymidylate synthase DNA polymorphisms and gender on the clinical evolution of patients with advanced colorectal cancer. Oncol Rep (2010) 0.83
The influence of CYP2C19 genetic polymorphism on the pharmacokinetics/- pharmacodynamics of proton pump inhibitor-containing Helicobacter pylori treatments. Curr Drug Metab (2012) 0.83
[Common errors in the management of the seriously ill patient with inflammatory bowel disease]. Gastroenterol Hepatol (2007) 0.82
Intravenous iron in inflammatory bowel diseases. Curr Opin Gastroenterol (2013) 0.82
Effectiveness of infliximab after adalimumab failure in Crohn's disease. World J Gastroenterol (2012) 0.82
Role of growth factors in the development of lymphangiogenesis driven by inflammatory bowel disease: a review. Inflamm Bowel Dis (2010) 0.82
Therapeutic guidelines on ulcerative colitis: a GRADE methodology based effort of GETECCU. Gastroenterol Hepatol (2013) 0.82
The role of tacrolimus in inflammatory bowel disease: a systematic review. Dig Dis Sci (2006) 0.81
Preclinical evaluation of azathioprine plus buthionine sulfoximine in the treatment of human hepatocarcinoma and colon carcinoma. World J Gastroenterol (2011) 0.81
[First Spanish consensus on peptic ulcer bleeding management. Consenso sobre Hemorragia Digestiva por Úlcera Péptica]. Med Clin (Barc) (2010) 0.81
Probiotics for Helicobacter pylori eradication therapy: not ready for prime time. Rev Esp Enferm Dig (2013) 0.81
[Update on the efficacy of triple therapy for Helicobacter pylori infection and clarithromycin resistance rates in Spain (2007-2012)]. Gastroenterol Hepatol (2013) 0.81
Impact of current smoking on the clinical course of microscopic colitis. Inflamm Bowel Dis (2013) 0.81
Adalimumab is effective in long-term real life clinical practice in both luminal and perianal Crohn's disease. The Madrid experience. Gastroenterol Hepatol (2011) 0.81
Open-label infliximab therapy in ulcerative colitis: a multicenter survey of results and predictors of response. Hepatogastroenterology (2008) 0.81
[Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis on the use of anti-tumor necrosis factor drugs in inflammatory bowel disease]. Gastroenterol Hepatol (2013) 0.80
A new guidewire cannulation technique in ERCP: successful deep biliary access with triple-lumen sphincterotome and guidewire controlled by the endoscopist. Surg Endosc (2010) 0.80